BioNTech and Bristol Myers Squibb report Phase 2 lung cancer combo data
BioNTech and Bristol Myers Squibb announced results from the global Phase 2 ROSETTA Lung‑107 trial of pumitamig plus docetaxel in metastatic non‑small cell lung cancer patients who progressed after first‑line immunotherapy plus chemotherapy. The study of 50 patients showed a confirmed objective response rate of 36.7% and a median progression‑free survival of 6.9 months. Safety was manageable, with treatment‑related adverse events in 52.0% of patients and grade ≥ 3 events in 18.0%. The data were presented at the ESMO 2026 Congress and will inform ongoing Phase 3 programs.
Why it matters
The company says the results support continued advancement of pumitamig in multiple Phase 3 lung‑cancer trials, potentially expanding treatment options beyond docetaxel in the second‑line setting (). Investors should watch for subsequent trial readouts that could affect the valuation of both firms.
Key facts
- 1The Phase 2 ROSETTA Lung‑107 trial evaluated pumitamig 1400 mg plus docetaxel every three weeks in patients with metastatic NSCLC who progressed after immunotherapy plus chemotherapy. stocktitan.net
- 2The data cut‑off on July 10 2026 included 50 patients, with a median follow‑up of 12.2 weeks and 33 patients remaining on treatment. stocktitan.net
- 3Among 30 efficacy‑evaluable patients, the confirmed objective response rate was 36.7%. marketscreener.com
- 4The disease control rate was 90.0% in the efficacy‑evaluable cohort. marketscreener.com
- 5Median progression‑free survival was 6.9 months (95 % CI: 4.2 – not reached) in the overall treated population of 50 patients. marketscreener.com
- 6Treatment‑related adverse events of any grade occurred in 52.0% of patients; grade ≥ 3 adverse events occurred in 18.0% of patients. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.